SOUTH SAN FRANCISCO, Calif., March 27 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc. announced today that it will present at the BioCentury and Thomson Financial Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City at 11:30 a.m. Eastern on Thursday, March 30, 2006. Paul Sekhri, President and CEO of Cerimon Pharmaceuticals, will provide a company and clinical development overview.
About Cerimon Pharmaceuticals
Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to bringing innovative therapeutics to patients with substantial, unmet medical needs. Headquartered in South San Francisco, Cerimon is engaged in the development and commercialization of therapeutics in the areas of autoimmune disease, inflammation and pain. The Company’s lead products are Simulect(R) (basiliximab), a monoclonal antibody which is being advanced towards Phase 2b studies for the treatment of inflammatory bowel disease, and two topical formulations of diclofenac, a non-steroidal anti-inflammatory drug (NSAID), in development for the treatment of mild to moderate chronic pain due to arthritis. Cerimon completed a Series A financing of $70M in October 2005.
For more information on Cerimon, please visit the Company’s Website at http://www.cerimon.com/ .
Cerimon Pharmaceuticals, Inc.
CONTACT: Paul Sekhri, President and CEO of Cerimon Pharmaceuticals, Inc.,+1-650-827-4000; or Justin Jackson, +1-212-213-0006, jjackson@burnsmc.com,or Jason Farber, +1-212-213-0006, jfarber@burnsmc.com, both of BurnsMcClellan, both for Cerimon Pharmaceuticals, Inc.
Web site: http://www.cerimon.com/
